PURPOSE OF REVIEW: The 2009 influenza pandemic introduced a new influenza A/H1N1 subtype in the human population. This pandemic 2009 influenza A/H1N1 virus has natural resistance to the adamantanes class and has a low threshold to become resistant to the neuraminidase class of antiviral drugs. This review describes recent findings on influenza antiviral resistance in pandemic 2009 influenza A/H1N1 virus. RECENT FINDINGS: Pandemic 2009 viruses have emerged with novel resistance patterns to the neuraminidase inhibitors. In addition, the identification of mutations that facilitated oseltamivir resistance in prepandemic influenza emphasizes the ability of influenza to become resistant to antiviral drugs without significant loss of fitness. SUMMARY: Novel initiatives are required to find and develop high genetic barrier influenza therapeutic regimens for effective treatment of severe influenza virus infections.
PURPOSE OF REVIEW: The 2009 influenza pandemic introduced a new influenzaA/H1N1 subtype in the human population. This pandemic 2009 influenzaA/H1N1 virus has natural resistance to the adamantanes class and has a low threshold to become resistant to the neuraminidase class of antiviral drugs. This review describes recent findings on influenza antiviral resistance in pandemic 2009 influenzaA/H1N1 virus. RECENT FINDINGS: Pandemic 2009 viruses have emerged with novel resistance patterns to the neuraminidase inhibitors. In addition, the identification of mutations that facilitated oseltamivir resistance in prepandemic influenza emphasizes the ability of influenza to become resistant to antiviral drugs without significant loss of fitness. SUMMARY: Novel initiatives are required to find and develop high genetic barrier influenza therapeutic regimens for effective treatment of severe influenza virus infections.
Authors: Sanmitra Barman; Lei You; Ran Chen; Vlad Codrea; Grace Kago; Ramakrishna Edupuganti; Jon Robertus; Robert M Krug; Eric V Anslyn Journal: Eur J Med Chem Date: 2013-11-07 Impact factor: 6.514
Authors: Michael G Sugiyama; Asela Gamage; Roman Zyla; Susan M Armstrong; Suzanne Advani; Andrew Advani; Changsen Wang; Warren L Lee Journal: J Virol Date: 2015-12-04 Impact factor: 5.103
Authors: Sachiko Seo; Janet A Englund; Jack T Nguyen; Sasithon Pukrittayakamee; Niklas Lindegardh; Joel Tarning; Paul A Tambyah; Christian Renaud; Gregory T Went; Menno D de Jong; Michael J Boeckh Journal: Antivir Ther Date: 2012-12-21
Authors: Juan Téllez-Sosa; Mario Henry Rodríguez; Rosa E Gómez-Barreto; Humberto Valdovinos-Torres; Ana Cecilia Hidalgo; Pablo Cruz-Hervert; René Santos Luna; Erik Carrillo-Valenzo; Celso Ramos; Lourdes García-García; Jesús Martínez-Barnetche Journal: PLoS One Date: 2013-07-02 Impact factor: 3.240
Authors: Christina Ehrhardt; Sabine Eva Dudek; Magdalena Holzberg; Sabine Urban; Eike Roman Hrincius; Emanuel Haasbach; Roman Seyer; Julia Lapuse; Oliver Planz; Stephan Ludwig Journal: PLoS One Date: 2013-05-23 Impact factor: 3.240